BioMed Central

BioMed Central is a publishing company specializing in open access scientific journals. It was an early adopter of article processing charges and influenced policies at institutions such as the Wellcome Trust, the National Institutes of Health, and the European Research Council. The publisher interacted with organisations including the Public Library of Science, the Committee on Publication Ethics, and CrossRef while operating within the ecosystems of Springer, Nature Research, and Taylor & Francis.

History

Founded in 2000 by Vitek Tracz, BioMed Central emerged during debates involving figures like Harold Varmus and organizations like the Public Library of Science and the Wellcome Trust. Early milestones included partnerships with the British Library and negotiations with the Research Councils UK and the National Institutes of Health. The company expanded its portfolio alongside competitors such as Elsevier, Wiley, and Springer, and its trajectory intersected with events involving the Research Excellence Framework and the Finch Report. In 2008 BioMed Central was acquired by Springer Science+Business Media, which later merged with Nature Publishing Group to form Springer Nature; this placed the publisher in the same corporate family as Nature, Scientific Reports, and Palgrave Macmillan. Throughout its development the firm engaged with bodies including the Committee on Publication Ethics, CrossRef, and the Directory of Open Access Journals while responding to policies from the European Commission and the Wellcome Trust.

Business Model and Open Access Policy

BioMed Central operated primarily on an article processing charge (APC) model, paralleling approaches advocated by advocates such as Harold Varmus and institutions like the Wellcome Trust, the Howard Hughes Medical Institute, and the European Research Council. Its model contrasted with subscription houses including Elsevier, Springer, and Taylor & Francis and informed debates involving the Finch Report, Plan S, and the Budapest Open Access Initiative. The publisher participated in agreements with university consortia such as Jisc and partnerships with funders like the National Institutes of Health and the Medical Research Council. Licensing at times invoked Creative Commons frameworks similar to those used by PLOS, Hindawi, and Frontiers, and its APC policies prompted scrutiny from watchdogs including the Committee on Publication Ethics and the Directory of Open Access Journals.

Journals and Subject Areas

The publisher hosted journals spanning biomedical disciplines, ranging from clinical medicine and genomics to public health and bioinformatics. Titles covered topics related to institutions and initiatives such as the Human Genome Project, the Global Fund, and the World Health Organization. Subject areas intersected with research communities centered at universities like University College London, Harvard University, Stanford University, and the University of Oxford, and engaged scholars associated with societies such as the Royal Society, the American Medical Association, and the American Association for the Advancement of Science. Journals addressed themes connected to pandemics investigated by the Centers for Disease Control and Prevention, parasitology work funded by the Wellcome Trust, and translational research coordinated with the National Institutes of Health and the European Medicines Agency. The portfolio positioned the publisher alongside other open access platforms such as PLOS Biology, eLife, and Scientific Reports.

Editorial and Peer Review Processes

Editorial operations involved editors drawn from universities and research organisations including Imperial College London, King's College London, the University of Cambridge, and Massachusetts General Hospital. Peer review practices referenced standards debated by the Committee on Publication Ethics, the International Committee of Medical Journal Editors, and ResearchGate discussions among scholars from institutions such as Yale University, Columbia University, and the University of California, San Francisco. The company adopted processes comparable to those used by PLOS, eLife, and Elsevier journals, engaging reviewers affiliated with networks like ORCID, Publons, and CrossRef. Handling editors managed submissions informed by policies from funders such as the National Institutes of Health, the Wellcome Trust, and the European Commission, and worked with indexing services including PubMed, Scopus, and Web of Science.

Impact, Metrics, and Criticism

BioMed Central's journals were indexed in databases such as PubMed Central, Scopus, and Web of Science, contributing to citation metrics tracked by Clarivate and Altmetric, and influencing rankings used by universities during Research Excellence Framework assessments. The publisher received praise from advocates of open access such as Peter Suber and saw its model contrasted with subscription publishers like Elsevier and Springer. Criticism included debates over APC levels raised by researchers at institutions including the Max Planck Society, the Wellcome Trust, and the European Commission, concerns voiced in editorials in journals such as The Lancet and Nature, and scrutiny by organisations like the Committee on Publication Ethics. Discussions touching on Plan S, the Finch Report, and the Budapest Open Access Initiative framed assessments of sustainability, equity, and influence among stakeholders such as funders, libraries, and universities including the University of Oxford, Harvard University, and the University of Toronto.

Category:Academic publishing Category:Open access publishers